Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OSTX OS Therapies	$2.06 -4.2%	$1.79	$1.12 ▼ $7.00	$67.99M	N/A	730,258 shs	484,126 shs
PYRGF PyroGenesis Canada	$0.26 -2.8%	$0.32	$0.25 ▼ $0.71	$48.40M	0.83	12,583 shs	1,455 shs
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs
TRLPF Acerus Pharmaceuticals	$0.22	$0.22	$0.08 ▼ $0.34	$56.90M	2.6	5,474 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OSTX OS Therapies	0.00%	+19.08%	+22.62%	+25.61%	-35.83%
PYRGF PyroGenesis Canada	0.00%	-7.82%	-19.27%	-20.49%	-56.25%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%
TRLPF Acerus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OSTX OS Therapies	2.2665 of 5 stars	3.7	0.0	0.0	0.0	2.3	0.8	0.6
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRLPF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OSTX OS Therapies	3.40	Buy	$18.00	773.79% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
SYN Synthetic Biologics	0.00	N/A	N/A	N/A
TRLPF Acerus Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYN, TRLPF, OSTX, and PYRGF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	$9.14M	5.30	N/A	N/A	($0.01) per share	-25.81
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	$4.95 per share	N/A
TRLPF Acerus Pharmaceuticals	$7.38M	7.71	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	8/19/2025 (Confirmed)
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
SYN Synthetic Biologics	-$14.27M	-$1.21	N/A	N/A	N/A	N/A	-26.14%	-22.74%	N/A
TRLPF Acerus Pharmaceuticals	-$18.79M	-$0.08	N/A	∞	N/A	-254.66%	-346.72%	-94.54%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	N/A
TRLPF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OSTX OS Therapies	N/A	0.76	0.76
PYRGF PyroGenesis Canada	N/A	0.60	0.50
SYN Synthetic Biologics	N/A	4.14	4.14
TRLPF Acerus Pharmaceuticals	0.64	1.35	0.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OSTX OS Therapies	N/A
PYRGF PyroGenesis Canada	0.03%
SYN Synthetic Biologics	74.38%
TRLPF Acerus Pharmaceuticals	0.02%

Insider Ownership

Company	Insider Ownership
OSTX OS Therapies	13.80%
PYRGF PyroGenesis Canada	47.68%
SYN Synthetic Biologics	2.15%
TRLPF Acerus Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OSTX OS Therapies	N/A	31.62 million	N/A	N/A
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data
SYN Synthetic Biologics	16	15.84 million	15.50 million	Not Optionable
TRLPF Acerus Pharmaceuticals	29	258.62 million	N/A	Not Optionable

SYN, TRLPF, OSTX, and PYRGF Headlines

Recent News About These Companies

Takeda Pharmaceutical Co. Ltd. ADR

February 8, 2024 | wsj.com

Other OTC Pharmaceuticals - Lithuania

September 17, 2023 | statista.comS

2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit

January 1, 2023 | seekingalpha.com

Acerus Reports Second Quarter 2022 Financial Results

August 9, 2022 | financialpost.comF

Acerus Reports Fourth Quarter and Full Year 2021 Financial Results

March 15, 2022 | financialpost.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYN, TRLPF, OSTX, and PYRGF Company Descriptions

OS Therapies NYSE:OSTX

$2.06 -0.09 (-4.19%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.02 (+0.97%)

As of 08/15/2025 07:25 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

PyroGenesis Canada NASDAQ:PYRGF

$0.26 -0.01 (-2.82%)

As of 08/15/2025 12:43 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Synthetic Biologics NYSEAMERICAN:SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Acerus Pharmaceuticals OTCMKTS:TRLPF

$0.22 0.00 (0.00%)

As of 07/21/2023

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time